TY - JOUR
T1 - Mapping patterns of locoregional recurrence following contemporary treatment with radiation therapy for breast cancer
T2 - A multi-institutional validation study of the ESTRO consensus guideline on clinical target volume
AU - Chang, Jee Suk
AU - Lee, Jeongshim
AU - Chun, Mison
AU - Shin, Kyung Hwan
AU - Park, Won
AU - Lee, Jong Hoon
AU - Kim, Jin Hee
AU - Yoon, Won Sup
AU - Lee, Ik Jae
AU - Kim, Juree
AU - Park, Hye Li
AU - Kim, Yong Bae
N1 - Funding Information:
This article was supported by the Korean Radiation Oncology Group (KROG 15-07).
Publisher Copyright:
© 2017 Elsevier B.V.
PY - 2018/1
Y1 - 2018/1
N2 - Background and purpose: To validate the ESTRO guideline on clinical target volume (CTV) delineation for breast cancer using a multi-centre dataset. Materials and methods: Patients with axial imaging of gross locoregional recurrence (LRR) were identified from 10 participating institutions. All patients received RT, albeit not to all regional node. The location of LRR was transferred to the corresponding area on representative axial computed tomography images and compared with ESTRO-CTV. Results: The locations of LRRs in 234 patients with 337 recurrence lesions were mapped. The ESTRO-CTV encompassed 97.6% of all LRRs, except in lymph node level 4 and the pectoralis muscle. Although 8.8% of level 4 failures occurred outside the ESTRO-CTV, cranial to the subclavian artery, all nodes were located within 6 mm cranially. Another 20% occurred posterolateral to anterior scalene muscles; however, 11/16 cases had simultaneous multiple lymph node recurrences, and 8/16 initially had N2-3 tumours. Local recurrence at the pectoralis muscle was prominent in patients undergoing mastectomy but not breast-conservation surgery (28% vs. 2.9%, P =.001). Conclusions: Our mapping data demonstrated that the ESTRO-CTV, with some considerations, successfully encompassed most LRRs in patients undergoing contemporary management, thus validating ESTRO-CTV to be valuable for highly conformal radiation therapy techniques.
AB - Background and purpose: To validate the ESTRO guideline on clinical target volume (CTV) delineation for breast cancer using a multi-centre dataset. Materials and methods: Patients with axial imaging of gross locoregional recurrence (LRR) were identified from 10 participating institutions. All patients received RT, albeit not to all regional node. The location of LRR was transferred to the corresponding area on representative axial computed tomography images and compared with ESTRO-CTV. Results: The locations of LRRs in 234 patients with 337 recurrence lesions were mapped. The ESTRO-CTV encompassed 97.6% of all LRRs, except in lymph node level 4 and the pectoralis muscle. Although 8.8% of level 4 failures occurred outside the ESTRO-CTV, cranial to the subclavian artery, all nodes were located within 6 mm cranially. Another 20% occurred posterolateral to anterior scalene muscles; however, 11/16 cases had simultaneous multiple lymph node recurrences, and 8/16 initially had N2-3 tumours. Local recurrence at the pectoralis muscle was prominent in patients undergoing mastectomy but not breast-conservation surgery (28% vs. 2.9%, P =.001). Conclusions: Our mapping data demonstrated that the ESTRO-CTV, with some considerations, successfully encompassed most LRRs in patients undergoing contemporary management, thus validating ESTRO-CTV to be valuable for highly conformal radiation therapy techniques.
UR - http://www.scopus.com/inward/record.url?scp=85031430519&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031430519&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2017.09.031
DO - 10.1016/j.radonc.2017.09.031
M3 - Article
C2 - 29050960
AN - SCOPUS:85031430519
SN - 0167-8140
VL - 126
SP - 139
EP - 147
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
IS - 1
ER -